HER2/Neu Protein Over-Expression in Patients with Gastric and Gastro-Esophageal Junction Carcinoma Seen at Kenyatta National Hospital, Kenya
View/ Open
Date
2014Author
Ali, Hussein A
Rogena, Emily
Omulo, TM
Ndaguatha, PLW
Language
enMetadata
Show full item recordAbstract
Background:
Gastric
cancer
in
Kenya
is
ranked
third
in
both
males
and
females.
Most
patients
present
clinically
with
advanced
unsusceptible
disease
have
poor
prognosis
despite
administration
of
standard
chemotherapy.
Human
epidermal
growth
factor
receptor–2
(HER-2)
over
expression
in
gastric
cancer
is
related
to
poor
outcome.
Advances
in
molecular
therapy,
have
identified
HER-2
to
be
an
important
component
in
the
treatment
of
advanced
gastric cancer. The prevalence of HER-2 in Kenya is unknown.
Objective:
To
determine
the
prevalence
of
HER-2
overexpression
in
patients
with
gastric
and
gastrooesophageal
junction carcinoma at Kenyatta National Hospital.
Methodology:
Descriptive
Cross
sectional
study
on
patients
with
histological
diagnosis
from
endoscopic/
resection
specimens
of
gastric
or
GEJ
cancer
at
KNH.
A
sample
of
66
patients
was
selected
by
progressive
sampling.
Approval
was
obtained
from
the
KNH/UON
ethics
and
research
committee.
Data
was
collected
using
a
pretested
questionnaire.
All
tissue
blocks
were
tested
for
HER-2
receptor
protein
using
IHC.
Data
entry
and
analysis
was done via SPSS version 21.0.
Results:
Study
sample
of
66
patients
were
included
in
the
study
with
a
mean
age
of
60.7
years
and
males
consisting
of
66.7%.
42
specimens
were
obtained
from
OGD
and
24
from
surgically
resected
specimens.
Approximately
91%
of
the
tumours
were
located
in
the
gastric
region.
Gastric
adenocarcinoma
accounted
for
89.4%
(N=59)
mainly
intestinal
(78.8%,
N=52)
and
diffuse
(9.1%,
N=6)
while
1.5%
(N=1)
was
adeno-squamous.
HER-2
over-expression
was
diagnosed
in
42.4%
(N=28)
of
patients.
HER-2
over-expression
was
not
significantly
associated
with
age
(P=0.844)
and
gender
(P=0.682).
The
anatomical
site
was
not
significantly
associated
with
HER-2
over-expression
(P=1).
HER-2
over-expression
was
found
mostly
in
adenocarcinoma
(96.4%)
compared
to
3.6%
in
adeno-squamous,
with
intestinal
type
showing
highest
rate
of
over-expression
(87.5%)
compared
to
diffuse
(12.5%).
Conclusion:
HER-2
over-expression
was
found
to
be
higher
in
our
study
(42.4%)
compared
to
most
of
the
studies. HER-2 over-expression is observed predominantly in intestinal type of gastric and GEJ adenocarcinomas.
URI
http://www.omicsonline.org/open-access/herneu-protein-overexpression-in-patients-with-gastric-and-gastro-esophageal-junction-carcinoma-seen-at-kenyatta-national-hospital-kenya-2157-2518-5-186.php?aid=30877http://hdl.handle.net/11295/87444
Citation
J Carcinog Mutagen 2014, 5:5Collections
- Faculty of Health Sciences (FHS) [10378]